Weight management and current options in pharmacotherapy: Orlistat and sibutramine

被引:59
作者
Leung, WYS [1 ]
Thomas, GN [1 ]
Chan, JCN [1 ]
Tomlinson, B [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Clin Pharmacol, Shatin, Peoples R China
关键词
obesity; weight management; antiobesity drugs; orlistat; sibutramine;
D O I
10.1016/S0149-2918(03)90009-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Chronic obesity is associated with various cardiovascular disorders, including diabetes, dyslipidemia, and hypertension. Pharmacotherapy with antiobesity agents is an important management strategy in conjunction with lifestyle interventions. Objective: This article describes the pharmacologic management of obesity, concentrating on orlistat and sibutramine. Methods: Relevant articles were identified through a MEDLINE search (1966-February 2002) using the terms obesity, overweight, weight loss, antiobesity drugs, orlistat, and sibutramine. The search for efficacy trials was limited to randomized controlled studies of >6 months' duration. Also included in the review were relevant references cited in the bibliographies of identified articles, news reports, and the authors' own data. Results: Orlistat reduces fat absorption by inhibiting gastrointestinal lipases. In randomized, controlled trials of up to 2 years' duration, orlistat plus a hypocaloric diet produced significantly greater weight loss than placebo (P < 0.001). In the maintenance phase, patients taking orlistat had less weight regain than did placebo recipients. The weight reduction with orlistat was also associated with a significant improvement in control of cardiovascular risk factors (P < 0.05). Unlike orlistat, sibutramine works by suppressing appetite; its efficacy, however, was similar to that of orlistat in the identified clinical trials. Orlistat was associated primarily with gastrointestinal side effects. Use of orlistat was associated with minimal drug interactions, except with cyclosporine, with which it should not be taken. Sibutramine was also well tolerated, although it may cause dry mouth, anorexia, and insomnia, and should be used with caution in patients at risk for cardiovascular disease. Conclusions: Orlistat and sibutramine demonstrated a favorable efficacy and safety profile in randomized controlled trials. Current evidence supports their use as adjuncts to lifestyle modifications in the treatment of obesity. Copyright (C) 2003 Excerpta Medica, Inc.
引用
收藏
页码:58 / 80
页数:23
相关论文
共 84 条
[1]  
Abbott Laboratories, 2000, RED PACK INS
[2]  
[Anonymous], 2000, ASIA PACIFIC PERSPEC
[3]  
[Anonymous], 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
[4]  
[Anonymous], 1998, PREV MAN GLOB EP
[5]   Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine [J].
Apfelbaum, M ;
Vague, P ;
Ziegler, O ;
Hanotin, C ;
Thomas, F ;
Leutenegger, E .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :179-184
[6]   Absence of cardiac valve dysfunction in obese patients treated with sibutramine [J].
Bach, DS ;
Rissanen, AM ;
Mendel, CM ;
Shepherd, G ;
Weinstein, SP ;
Kelly, F ;
Seaton, TB ;
Patel, B ;
Pekkarinen, TA ;
Armstrong, WF .
OBESITY RESEARCH, 1999, 7 (04) :363-369
[7]   Sibutramine produces dose-related weight loss [J].
Bray, GA ;
Blackburn, GL ;
Ferguson, JM ;
Greenway, FL ;
Jain, AK ;
Mendel, CM ;
Mendels, J ;
Ryan, DH ;
Schwartz, SL ;
Scheinbaum, ML ;
Seaton, TB .
OBESITY RESEARCH, 1999, 7 (02) :189-198
[8]   Double-blind randomized placebo-controlled trial of sibutramine [J].
Bray, GA ;
Ryan, DH ;
Gordon, D ;
Heidingsfelder, S ;
Cerise, F ;
Wilson, K .
OBESITY RESEARCH, 1996, 4 (03) :263-270
[9]   Body-mass index and mortality in a prospective cohort of US adults [J].
Calle, EE ;
Thun, MJ ;
Petrelli, JM ;
Rodriguez, C ;
Heath, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (15) :1097-1105
[10]  
Canovatchel W, 1997, 16 INT DIAB FED C JU